New frontiers in cardiovascular risk reduction: people with diabetes and dyslipidaemia

Diabetes, Obesity and Metabolism
Volume 21, Supplement 1, April 2018

Editor: Richard Donnelly, MD, PhD

Release date: April 2019
Expiration date: April 2020
Estimated time to complete activity: 1.5 hours

This activity is provided by John Wiley & Sons, Inc.

Publication of this supplement is made possible by an educational grant from Sanofi US and Regeneron Pharmaceuticals


 


Educational Objectives
Upon completion of this educational activity, participants will be better able to:
• Describe the pathophysiological mechanisms of dyslipidemia in patients with diabetes
• Outline the factors underlying cardiovascular risk in patients with diabetes
• Describe the mechanism of action of PCSK9 inhibitors
• Discuss clinical trial data pertaining to the use of PCSK9 inhibitors in patients with diabetes

Activity Disclosures
This activity is supported by an educational grant from Sanofi-Regeneron.

Editor Richard Donnelly reports no conflicts of interest or financial relationships relevant to this activity.

Authors
Kausik Ray discloses investigative grants from Sanofi-Regeneron, Amgen, Pfizer, and MSD, advisory board fees from IONIS and Mylan, Speaker fees from Takeda, Cipla, Janssen, Pfizer and Algorithm, honorarium for principal investigator on steering committee for The Medicines Company, study committee membership, advisory board and speaker fees from Sanofi and Amgen, study committee membership and speaker fees from Kowa, advisory board and speaker fees from Regeneron, study committee membership fees from Esperion and Cerenis, advisory board and speaker fees from Novo Nordisk and Boehringer Ingelheim, study committee membership and advisory board fees from Lilly, study committee membership and principal investigator fees from Resverlogix, and drug safety monitoring board member fees from Abbvie.
Jennifer Robinson discloses institutional research grants from Acasti, Amarin, Amgen, Astra-Zeneca, Esai, Esperion, Merck, Sanofi-Regeneron and Takeda, and consultant fees from Amgen, Merck, Novartis, Novo-Nordisk, Pfizer and Sanofi-Regeneron.
Bertrand Cariou discloses research grants from Amgen, Sanofi-Regeneron and Pfizer, as well as consulting honorarium from Amgen and Sanofi-Regeneron.
Satya Dash discloses advisor honorarium and speaker fees from Eli Lilly.
Lawrence Leiter discloses research support and honorarium rom Astrazenica, Amgen, Esperion, HLS, Kowa, Merck, Sanofi and The Medicines Company.
Gerald Watts discloses research grants from Amgen and Sanofi-Regeneron, and Advisory board fees from Amgen, Sanofi-Regeneron and Gemphire.

The remaining authors reported no conflicts of interest or financial relationships relevant to this article.

This activity underwent peer review in line with the standards of editorial integrity and publication ethics of Diabetes, Obesity and Metabolism. Conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest.

Accreditation
John Wiley and Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

John Wiley and Sons, Inc. designates this journal-based CME activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within 1.5 hours. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to two years from initial publication. Additionally, up to 3 attempts and a score of 70% or better is needed to pass the post test.